Disc Medicine plans FDA filing after positive bitopertin Phase 3 data
The company reported lower PPIX levels and more pain-free light exposure, and plans a new FDA submission by year-end.
Makkler Newsroom · Oct 20, 03:14 PM · 1 min read
Market closed· · USD · Data may be delayed
Avg. target $126.77 (+65.5%)
Prices may be delayed and are for informational purposes only - not investment advice.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.